| INTRODUC TI ON
Protection against pathogens is achieved through the coordinated actions of the innate and the adaptive arms of the immune system.
Newborns rely heavily on their innate immune defenses as their "educated" adaptive immunity fully develops only later, in the early years of life. 1 Of the five antibody classes, IgG is the most prevalent in serum and certain mucosal tissues such as the airways, distal gastrointestinal tract and genitourinary tract, and has long been known to be the only class, that is, actively transferred from the mother to the fetus across the placenta by an active, neonatal Fc receptor (FcRn) mediated process during pregnancy, thus conferring shortterm passive immunity and protection against infections to the newborn during the first months of life. [2] [3] [4] Indeed, at the 32nd week of
In humans, the active role of this receptor starts early in fetal development and increases progressively from the early second trimester until the end of pregnancy. 5 Because of the great importance of acquiring maternal antibodies that can provide protection early in life, investigations into the mechanisms behind this pattern have been reported several times since the early 1980s. However, partly because of the very limited access to fetal samples (blood/placenta) in the first and second trimester, the vast majority of these reports were detailed reviews about the chemistry and functional physiology of the FcRn receptor, or studies using the ex-vivo placental transfer model, but that were not verified in human clinical samples. 15 In fact, there are only limited number of reports of FcRn expression in early human life but have not been correlated with IgG levels.
16
We now report on the placental transmission of IgG antibodies in clinical samples. Our specific objectives were to (i) investigate if there is a relationship between maternal and the neonatal IgG levels, and (ii) compare serum IgG levels and FcRn expression in placental tissue in preterm and term neonates according to gestational age (third trimester of pregnancy).
| MATERIAL S AND ME THODS

| Patients
The present work was conducted in 85 women between 19 and 40 years of age and their 90 offspring (10 twins), admitted to the Obstetrics Department at the Clínica Universitaria Reina Fabiola, Córdoba, Argentina, between April and October 2013. All women that agreed to participate in this study signed an informed consent.
Patients presenting prenatal diagnosis of placental pathology, immunological deficiencies, or autoimmunity were excluded from the study as were newborns presenting any genetic syndrome diseases. 
| Placental FcRn receptor
The placentas were obtained after birth and immediately fixed using a 10% buffered formaldehyde solution until further processing.
Some placentas were lost during the process because of technical problems during urgency of a preterm delivery. Therefore, a subgroup of 31 placentas was analyzed.
To quantify the expression of the FcRn receptor, the placental tis- 
| Ethical approval
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| Data analysis
Data analysis was performed using the Infostat statistical software (2013 version). 20 Values were expressed as median and range (Q1-Q3).
To check the assumptions of normality and variance homogeneity, diagnostic techniques based in the residuals were applied. Accordingly, the data were analyzed using the Wilcoxon Mann-Whitney test or
Kruskal-Wallis test and Dunn's post-hoc test for multiple comparisons. In the case of categorical variables, the chi square test was applied. The significance level for all statistical tests was set at 0.05.
| RE SULTS
A total of 85 blood samples were obtained from the mothers, and 90 samples were obtained from the newborns umbilical cord. All newborns had a gestational age greater than 32 weeks; ten newborns (11.1%) were twins, 41 (45.6%) were born from primiparous mothers and 49 (54.4%) from multiparous mothers. The full clinical and biochemical data from maternal and cord blood IgG levels in the four groups are shown in Table 1 .
The total IgG levels in both mothers and neonates were found to be within the normal range as published in the literature.
In the mothers, a slight increase in IgG levels was observed toward the end of gestation, reaching significantly higher levels in
Group IV (38-41 weeks of gestation; P < .0001; Table 1 ); additionally a linear regression analysis of the data also showed a positive and significant correlation between increased IgG levels and gestational age (P < .001; slope: 2.38; r 2 = .21).
No significant differences were found when analyzing the influence of the mothers' age or number of previous gestations on maternal IgG levels (P = .85 and .07 respectively).
In the newborns, the preterm groups (I, II and III) showed a significantly lower IgG level than those individuals born at full term (P < .0001; Table 1 ). IgG levels increased by 2.44 mg/dL per week throughout gestation.
With respect to the impact of the newborn weight at birth, a regression analysis revealed that IgG levels increased significantly by 0.014 mg/dL per gram of body weight during the third trimester of gestation (P < .001; Figure 2 ).
Neither sex of the individual, age of the mother, or number of previous gestations influenced the newborns' IgG levels (P = .98; P = .53 and P = .47 respectively).
The total IgG levels detected in the newborns correlated with their mothers IgG levels, increasing progressively by 0.40 mg/dL for every 1.0 mg/dL of increase in the mother, and reached a significantly higher value toward the end of gestation in week 38 (Group IV) (P < .0001; Figure 3 ). Finally, IgG levels were significantly higher in the newborns than in their mothers in all four groups studied (P ≤ .05, Table 1 ). Neonate´s IgG level (mg/dL) P < .001; r 2 = .16 P = .01). In a further analysis, we observed that expression of the receptor increased significantly from week 36 of gestation onwards (Groups III and IV, P = .004, Figure 4 ).
Finally, an increase in the area of placental tissue expressing
FcRn was associated with an increase in IgG levels in the newborns (P < .0053; slope= 0.02; r 2 = .24) ( Figure 5 ).
| D ISCUSS I ON
Newborns, especially preterm infants, have an immature immune system that makes them a vulnerable population with high infectionassociated morbidities and mortality rates. 21, 22 Premature neonates are even more susceptible to infections due to several factors, including immature mechanical barriers, limited neutrophils function, low plasma concentrations of specific antibodies, low activities of the complement system proteins, and poor cooperation between T and B lymphocytes. This favors bacterial translocation across the intestinal epithelium and dissemination to other organs and tissues, thereby increasing the risk of systemic infections and potential for sepsis.
23-25
As previously mentioned, the immunoglobulins of the fetus consist almost entirely of maternal immunoglobulin G (IgG) transferred across the placenta. Such transplacental transfer of immunoglobulins provides temporary protection to the newborn against antigens that the mother had been exposed to during her own life. 24 Because of the great importance of this process, we investigated in a clinical setting the placental transmission of IgG antibodies in term and preterm newborns.
In the present work, we found that through the third trimester of gestation, total IgG levels in both mothers and neonates showed a significant increase toward the end of gestation.
Surprisingly in the mothers, both statistical tests applied indicated a mild, yet significant increase in IgG levels over the course of the last trimester. A large number of studies have been conducted on the relationship between IgG levels during pregnancy in the first, second, and the third trimester, reporting a significant drop throughout gestation. 26 This gradual decline in IgG was described as a consequence of the physiological expansion of maternal blood volume (hemodilution) and is consistent with a similar change in, that is, albumin levels. 26 However, little is known about the subtle changes developed exclusively during the third trimester. To our knowledge, only a few studies have investigated this relationship and they reported no significant variations in maternal IgG concentrations between weeks 28 and 42 of gestation, 26 or during the last 8 weeks of pregnancy. 27 One report in Brazilian mothers suggested that although not statistically significant, mothers of preterm babies had lower IgG levels as compared with term babies' mothers. 24 The reason for the slightly higher IgG levels found in our study remains unclear, although we might speculate a higher incidence of (subclinical) infections. We should also note that the higher data variation in groups III and IV could factor in to the trend we observed (Table 1) . Newborn`s IgG levels (mg/dL) FcRn expression area (%) P < .0053; r 2 = .24
Regarding the newborns, our results were consistent with the 30 Similarly, other authors assert that the immune transfer begins slightly earlier at 16 weeks of gestation, and that between the 22nd and 26th week, the level of fetal IgG increases rapidly doubling the IgG concentration at the end of gestation. 31 The greatest rate of antibody transfer to the fetus is after 34 weeks of pregnancy. Also, in all four groups studied in our work, the newborn's IgG levels exceeded their mother's values by a ~2.4%. Several studies have described similar findings. As human pregnancy progresses, fetal/newborn IgG levels continuously increase to reach and even surpass maternal levels at the end of the third trimester, resulting in a fetal:maternal ratio higher than one and sometimes reaching more than twice the maternal concentrations at the time of delivery.
32-35
Assuming that these levels of IgG in the fetus are entirely of maternal origin, this would remarkably suggest that FcRn is able to transport this macromolecule against a concentration gradient.
On the other hand, our results agree with those reported by Palmeira et al, 25 who found that maternal age and parity do not seem to influence placental antibody transfer.
In our study, IgG was observed to increase significantly with the newborns weight at birth; it is likely that this association is due to the fact that infants delivered at later gestational weeks usually present a higher body weight. 27 However, some, but not all investigators also have noted reduced circulating IgG concentrations in low birth weight infants, compared to those of similar gestational age with normal birth weight. 36 This suggests that for a given gestational age, placental insufficiency may limit IgG transfer to the fetus. 37 Finally, the present work also demonstrated that a higher expression of the placental neonatal receptor FcRn was detected in placentas obtained from newborns at week 36 of gestation onwards. This is consistent with previous observations that expression of the FcRn receptor is dependent on gestational age and is at its highest in the third trimester of human pregnancy. 25, 38 In this regard, it is known that in placental tissues these receptors are mainly located in the apical side and cytoplasm of the syncytiotrophoblast. 39 At early stages of pregnancy, the inner cytotrophoblast forms a continuous layer between the syncytiotrophoblast and the stromal cells. Cytotrophoblast cells neither express FcRn, 9 nor contain IgG, and may prevent further penetration of the villi by IgG. 40 However, late in this period, the FcRn is already expressed. 9 As gestation progresses and after the fourth month of pregnancy, the cytotrophoblast layer slowly disappears from the walls of the tertiary villi and becomes discontinuous, when the chorionic villi surface increments and expands, therefore exposing the syncytiotrophoblast cells to maternal blood vessels. 41 It is in this stage of gestation when the receptor can be exposed and the active transport of IgG begins. Experimental data obtained in rats indicated that the increasing total IgG levels during gestation coincide with an increase in FcRn expression in the placental tissue throughout pregnancy. 
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